Introduction
Imatinib (Gleevec, STI-571) is a small molecule that targets the BCR-ABL tyrosine kinase and is effective in the treatment of BCR-ABL-positive chronic myeloid leukemia (CML). Although imatinib has been remarkably successful in reducing the tumor burden and suppressing the progression of patients in the chronic phase of CML, it has been less successful in the treatment of the accelerated phase of the disease. Although point mutations in the ABL kinase domain seem to be the main cause of secondary resistance to imatinib, such point mutations do not seem to account for all of the resistance observed in patients with the accelerated form of CML (Gorre et al., 2001; Khorashad et al., 2006; O'Hare et al., 2006; Sherbenou and Druker, 2007) . One correlation that has been observed in leukemic samples from untreated patients as the disease progresses is increased expression of BCR-ABL. This has led to the speculation that the amount of BCR-ABL expressed by tumor cells contributes to the sensitivity of cells to imatinib (Keeshan et al., 2001; Barnes et al., 2005a; Modi et al., 2007) . Whether the increase in BCR-ABL simply requires a higher level of imatinib to suppress or induces more qualitative changes in intracellular signaling pathways leading to imatinib resistance has not been examined.
BCR-ABL transformation is associated with cellautonomous proliferation and increased glucose metabolism (Barnes et al., 2005b; Modi et al., 2007; Kominsky et al., 2009) . The effects of BCR-ABL on glucose uptake exceed the metabolic needs of the cells and excess glucose carbon is secreted from the transformed cells in the form of lactate. This metabolic conversion in a cell capable of oxidative phosphorylation is termed aerobic glycolysis or the Warburg effect. Recently, we showed in nontransformed cells that when growth factor-induced glucose uptake exceeded cellular needs, the cells underwent an induction of hypoxiainducible factor-1a (HIF-1a) . The consequent HIF-1a-mediated reprograming of glucose metabolism directs glycolytic pyruvate away from the mitochondria, converting it into lactate that is secreted from the cell . The consequence of this growth factor-induced nonhypoxic induction of HIF-1a is that the resulting metabolic reprograming leads to a loss of ribose produced by the oxidative arm of the pentose phosphate pathway (PPP) and tricarboxylic acid cycle (TCA) cycle intermediates required for macromolecular synthesis and an impaired ability to proliferate. Whether similar changes occur during oncogene-induced aerobic glycolysis has not been investigated.
Recently, we along with others have observed that BCR-ABL-transformed cells that survived in the presence of continuous imatinib treatment displayed higher levels of BCR-ABL expression (Mahon et al., 2000) . In this report, we show that imatinib-resistant cells displayed increased aerobic glycolysis but decreased proliferation in vitro. Although the BCR-ABL tyrosine kinase activity could still be repressed by imatinib, pharmacologically relevant concentrations of imatinib failed to suppress cell proliferation. These results confirmed that the resistant cell lines lacked BCR-ABL mutations to confer imatinib resistance and suggested that the activation of compensatory pathways may be involved in maintaining the ability of cells to survive and proliferate in the presence of imatinib. The increased glycolysis and decreased cell proliferation in resistant cells were both found to depend on the nonhypoxic activation of HIF-1a. HIF-1a induction also shifted ribose synthesis preferentially to the nonoxidative arm of the PPP. Oxythiamine as an inhibitor of thiaminedependent enzymes in both the TCA cycle and the nonoxidative PPP could restore imatinib sensitivity in resistant cells in vitro. Combination therapy with oxythiamine and imatinib led to a synergistic reduction of in vivo growth of both imatinib-sensitive and imatinib-resistant tumor xenografts. In addition, oxythiamine enhanced the efficacy of imatinib in primary CML cells isolated from patients in the accelerated/ blastic phase of the disease. Together, the data suggest that the induction of HIF-1a in cells exhibiting a high level of BCR-ABL-induced glucose uptake contributes to their imatinib resistance.
Results
Imatinib-resistant cells have upregulated BCR-ABL protein level, increased glucose uptake and reduced cell proliferation To obtain cells that can survive persistent exposure to imatinib, we continuously cultured BCR-ABL-transformed murine hematopoietic BaF3 cells (BaF3/p210) (Carroll et al., 1997) in 500 nM imatinib (Deininger et al., 2005; Dewar et al., 2005) until the outgrowth of a resistant population was obtained. To confirm their imatinib resistance, we treated the selected cells along with isogenic nonselected cells with varying concentrations of imatinib for 2 days and measured cell proliferation. Sensitive cells displayed a dose-dependent suppression of proliferation, whereas resistant cells were unaffected over the same dose range (Figure 1a ) Glucose uptake. Cells were treated with imatinib overnight and replated at a density of 0.5 Â 10 6 per ml in refreshed medium for 24 h. The glucose content in medium supernatants was measured. Glucose uptake ¼ (glucose in the medium before treatmentÀglucose in the medium after imatinib treatment). The experiment was carried out in triplicate, and shown is the mean glucose uptake (mmol)/10 6 cells per 24 h ( ± s.d.) of a representative experiment. (d, h) Cell proliferation. Cells were grown in the absence (ÀIm) or presence ( þ Im) of imatinib (Im, 0.5 mM for BR and 1 mM for LR) at a starting concentration of 0.2 Â 10 6 per ml in triplicate and counted at 0, 24 and 48 h points, respectively. Shown is the mean cell concentration (10 6 per ml)±s.d. of a representative experiment.
HIF-1a control of nonoxidative PPP F Zhao et al Supplemental Figure 2a ). In contrast to the lack of change in proliferation and viability in cells expressing the mutant form of BCR-ABL (T315I; Supplemental Figures 1a and b) (Gumireddy et al., 2005) , higher concentrations of imatinib inhibited cell proliferation and induced cell death in a dose-dependent manner, suggesting that these cells selected for imatinib resistance still rely on BCR-ABL for their survival and proliferation. Consistent with their ability to continue to proliferate in the presence of imatinib at 500 nM, resistant cells maintained residual BCR-ABL activity, as shown by autotyrosine phosphorylation (Figure 1b) . Transient withdrawal of imatinib from culture led to a derepression of BCR-ABL kinase activity in resistant cells as evidenced by tyrosine phosphorylation and STAT5 phosphorylation (Figure 1b) . Therefore, resistant cells do not revert to the phenotype of imatinibsensitive cells on imatinib withdrawal and instead retain increased BCR-ABL levels. Metabolic profiling revealed that the resistant cells had a significantly higher glycolytic rate and their glucose consumption was not suppressed by imatinib, as compared with isogenic sensitive cells over the same dose range, although higher doses eventually caused decreased glucose consumption (Figure 1c) . In contrast to this, cells expressing the mutant form of BCR-ABL (T315I) did not show any change in glucose metabolism when high doses of imatinib were present in the culture (Supplemental Figure 1c) . Despite increased glucose metabolism, resistant cells showed a reduced proliferation rate in comparison with isogenic sensitive cells. This reduced proliferation was observed when cells QJ;were cultured in the presence or absence of imatinib ( Figure 1d ). When resistant and sensitive cells were cocultured in the absence of imatinib, sensitive cells consistently outcompeted resistant cells (data not shown).
We also obtained a human CML cell line similarly selected for imatinib resistance, LAMA-84-R (LR) (Mahon et al., 2000) . Consistent with observations in murine-resistant cells, human-resistant cells did not show suppression of either cell proliferation or glucose consumption when exposed to a range of imatinib doses that resulted in the suppression of the growth of isogenic control cells (Figures 1e and g and Supplemental Figure  2b ). Imatinib-resistant cells in the presence of imatinib at the physiological concentration (1000 nM) showed residual BCR-ABL kinase activity, as shown by STAT5 phosphorylation (Figure 1f ). However, on withdrawal of imatinib from resistant cells, increased BCR-ABL downstream signaling was observed, in comparison with isogenic control cells as indicated by STAT5 phosphorylation. As with murine cells, human imatinib-resistant cells also displayed increased glucose consumption rate, in comparison with isogenic control cells at all doses of imatinib tested (Figure 1g ). However, imatinib over 2000 nM led to sharp reductions in glucose consumption and cell proliferation in resistant cells. In addition, slower cell proliferation was observed in human imatinib-resistant cells as compared with that in sensitive cells (Figure 1h ).
Imatinib-resistant cells display activation of HIF-1a
When the glucose uptake of growth factor-stimulated cells exceeds the capacity of cells to assimilate glucose, the resulting mitochondrial reactive oxygen species leads to an induction of HIF-1a that is required to allow cells to secrete excess glycolytic pyruvate as lactate (Pelicano et al., 2006; Bell and Chandel, 2007; Lum et al., 2007; Pan et al., 2007) . Although this induction of HIF-1a promotes cell viability, it results in a paradoxical increase in glucose metabolism and a reduction in cell proliferation . Because imatinibresistant cells exhibited such a phenotype, we examined the expression of HIF-1a. Induction of HIF-1a at both mRNA and protein levels was observed under normoxic conditions in both the murine-transformed and human BCR-ABL-transformed cell lines selected for imatinib resistance (Figure 2 ). In addition, induction of multiple HIF-1a targets at the mRNA and/or protein levels was observed in resistant cell lines, including vascular endothelial growth factor A, phosphoglycerate kinase 1, pyruvate dehydrogenase kinase 1 and pyruvate kinase M2 isoform (Figures 2b and d and Supplemental Figure 3 ).
Imatinib-resistant cells have increased glucose flux for ribose synthesis through the nonoxidative arm of the PPP One potential mechanism by which HIF-1 induction affects cell growth is through its ability to impair TCA cycle flux and reduce glucose flux through the oxidative PPP (Gupte and Wolin, 2006; Tuttle et al., 2007) . However, hypoxia induces both pyruvate kinase M2 isoform and transketolase (Tkt) (Kress et al., 1998; Haseloff et al., 2006) . Because we observed the nonhypoxic induction of HIF-1a in imatinib-resistant cells, we sought to determine whether there was also an induction of pyruvate kinase M2 isoform and Tkt in resistant cells that resulted in an increased glycolytic flux through nonoxidative PPP. Expression of both pyruvate kinase M2 isoform and Tkt family genes was found to be elevated in resistant cells and resistant cells exhibited increased Tkt activity (Figures 2 and 3a and Supplemental Figure 3 ).
To measure the relative contribution of oxidative and nonoxidative PPP to ribose synthesis, we established a Induction of HIF-1a is sufficient to direct glucose-mediated ribose synthesis preferentially through the nonoxidative arm of the PPP To study whether activation of HIF-1 has a function in regulating the PPP, we cultured BCR-ABL-transformed imatinib-sensitive cells under hypoxic conditions (0.5% oxygen) for 2 days before 14 C-labeled glucose was added to the cell culture to evaluate the relative Tkt flux for ribose synthesis. As shown in Figure 4a , cells under hypoxic conditions showed a significant induction of nonoxidative PPP for their ribose synthesis, as a result of an increase in Tkt-mediated nonoxidative ribose synthesis and a reduction in glucose-6-phosphate dehydrogenase (G6PD)-mediated ribose synthesis. To further address whether HIF-1a is sufficient to promote glucose flux through nonoxidative PPP for ribose synthesis, we used 293T cell lines stably transfected with either vector or a nondegradable HIF-1a construct (HIF1A-DPA) in an inducible system (Figure 4c ), as previously reported by others (Kim et al., 2006; Papandreou et al., 2006) . Cells with HIF-1a induction also showed a decreased glucose flux through the oxidative arm of the PPP (G6PD flux) (Figure 4d ). Despite decreasing glucose flux through G6PD, HIF-1a induced the production of ribose 5-phosphate through the nonoxidative arm of the PPP (Figure 4e) .
We investigated the effect of inhibiting HIF-1a on the Tkt flux. Cells with a constitutive expression of HIF-1a short-hairpin RNA (shRNA) exhibited a decrease in the Tkt flux, which was correlated with reduced mRNA levels for all detectable Tkt family genes (Figures 4f and g ).
HIF-1a is required for the survival and proliferation of imatinib-resistant cells HIF-1a activation can promote viability in cells exhibiting a high rate of glucose uptake . An shRNA expression vector encoding a puromycin-resistance gene and engineered to stably express an shRNA against HIF-1a was transfected into imatinib-resistant cells . After 10 days of culture, during which the medium containing both imatinib and the selection drug puromycin was replaced every 2-3 days, few cells survived in the cultures transfected with the HIF-1a shRNA expression plasmid, whereas cultures transfected with control shRNA had undergone a fivefold expansion (Figures 5a and b and Supplemental Figure 6 ).
Transketolase is a component of HIF-1a-dependent imatinib resistance
Transketolase is an HIF-1a target gene that may contribute to the maintenance of nucleotide biosynthesis in BCR-ABL-transformed cells. To test whether the induction of Tkt expression is a component of HIF-1a-mediated imatinib resistance, we transfected a plasmid containing an shRNA against Tkt and a puromycinresistance gene into imatinib-resistant cells. We chose Tkt for knockdown in imatinib-resistant cells because its transcript abundance was over 1000-fold greater than either Tktl1 or Tktl2 (data not shown). After being transfected with either a Tkt shRNA expression plasmid or a plasmid containing a control shRNA, we cultured resistant cells (BR) in the presence of both imatinib and the selection drug puromycin with a change in medium every 2-3 days. After 10 days, cells transfected with control shRNA had expanded fivefold despite continuous imatinib treatment. In contrast, there were few surviving cells in cultures transfected with plasmid containing Tkt shRNA (Figure 5a ). This result was specific for the shRNA suppression of Tkt. When imatinib-resistant cells were first stably expressed with human Tktl1 (transketolaselike 1, a transketolase family gene) that lacks the Tkt shRNA sequence, the transfection of the Tkt shRNA plasmid had no effect on the ability of cells to grow in the presence of both imatinib and puromycin (Figure 5c ).
Oxythiamine inhibition of thiamine-dependent enzymes restores imatinib sensitivity in imatinib-resistant cells in vitro
Oxythiamine is an analog of thiamine, which is a cofactor of Tkt and of several TCA cycle enzymes. Oxythiamine specifically inhibited glucose-mediated ribose synthesis through the nonoxidative arm of the PPP (Tkt flux) (Supplemental Figures 4) . Furthermore, oxythiamine can selectively inhibit the proliferation of G6PD-deficient Chinese hamster ovary (CHO) cells, which rely exclusively on the nonoxidative PPP for ribose synthesis, without affecting the proliferation of parental CHO cells (Supplemental Figure 7) (Tuttle et al., 1992) . In low-thiamine medium, neither oxythiamine nor imatinib alone had an inhibitory effect on cell proliferation of murine-resistant cells (BR) over a 7-day treatment period (Figure 5d and Supplemental Figure 8 ). However, a combination of oxythiamine and imatinib resulted in an over 90% decrease in cell number. The inhibition of cell proliferation on combination treatment was also observed in human imatinibresistant cells (LR) (Figure 5e and Supplemental Figure 8 ). The inhibitory effect of combining oxythiamine and imatinib could be rescued by adding thiamine to the culture medium (Figures 5d and e) . (Druker et al., 1996) . or oxythiamine had no effect on overall tumor growth over a 2-week period. In contrast, the combination of imatinib with oxythiamine synergistically inhibited the growth of resistant-cell xenografts (Figure 5f ). An effect of oxythiamine when combined with imatinib was also observed in imatinib-sensitive tumors. For animals injected with imatinib-sensitive cells, when a subtherapeutic dose of imatinib was administered (100 mg/kg per day), no effect on tumor growth was seen (higher doses resulted in suppression of tumor growth, data not shown). Oxythiamine alone was also ineffective. However, when the suboptimal dose of imatinib was combined with oxythiamine therapy, a significant reduction in tumor growth was observed (Figure 5g ), same as shown in vitro (Supplemental Figure 9) .
Oxythiamine improves the efficacy of imatinib in primary CML cells isolated from patients in the accelerated/ blastic phase of the disease BCR-ABL amplification has been shown in patients with CML when the disease progresses into the accelerated/blastic phase and BCR-ABL-expressing cells become resistant to imatinib (Gorre et al., 2001; Barnes et al., 2005a ) (Supplemental Figure 10) . To show the effect of combining oxythiamine and imatinib on the proliferation of primary CML cells, we examined colony formation for mononuclear cells isolated from two patients with CML in the accelerated phase of the disease (Supplementary information). Colony formation in both patients was about 50% inhibited with imatinib treatment. Treatment with oxythiamine alone had no significant inhibitory effect. However, when cells were treated with oxythiamine and imatinib, the number of colonies was significantly reduced, compared with cells treated with imatinib alone. This inhibition of oxythiamine was specific because the colony formation could be rescued to the level comparable to imatinib treatment alone by the addition of thiamine ( Figure 6 ).
Discussion
The level of BCR-ABL expression increases as tumors progress from the chronic phase (Gorre et al., 2001) . Increased BCR-ABL has also been observed when BCR-ABL-transformed cells are selected for imatinib resistance in vitro (Mahon et al., 2000) (Figure 1) . Surprisingly, in this study, we show that imatinibresistant cells displayed an increase in glycolysis but a reduced rate of proliferation. The effect is reminiscent of the effects of HIF-1a induction in cells exhibiting aerobic glycolysis . We show that Figure 5 Inhibition of nonoxidative nucleotide synthesis restores imatinib sensitivity in resistant cells in vitro and in vivo. (a-c) BR cells were transfected with constructs containing either control short-hairpin RNA (shRNA) (CTL), an shRNA against hypoxiainducible factor-1a (HIF-1a) or an shRNA against Tkt (Tkt) and cultured in the presence of imatinib (0.5 mM) and the selection drug puromycin (2 mg/ml), with a change in medium every 2-3 days. After 10 days of puromycin selection, cells are shown by bright-field microscopy (a) and live cell counts were performed (b, c) from a representative experiment. Scale bars ¼ 20 mm. (d) The transketolase inhibitor, oxythiamine, in combination with imatinib suppressed cell proliferation in murine imatinib-resistant BR cells in vitro. Cells were plated at a density of 0.15 Â 10 6 per ml on day 0 and diluted every 2-3 days with fresh medium. After 7 days of culture, viable cells were counted and shown is the relative cell number compared with untreated cells ( ± s.d.) from a representative experiment. Oxythiamine (OT) was added to cultures at 300 mM, imatinib (Im) was added at 0.5 mM and thiamine (T) was added at 50 mM as indicated. (e) Oxythiamine in combination with imatinib suppressed cell proliferation in human imatinib-resistant LR cells in vitro. Cells were plated at a density of 0.3 Â 10 6 per ml on day 0 and diluted every 2 days with fresh medium. After 6 days of culture, viable cells were counted and shown is the relative cell number compared with untreated cells ( ± s.d.) from a representative experiment. Oxythiamine (OT) was added to cultures at 1 mM, imatinib (Im) was added at 1 mM and thiamine (T) was added at 150 mM as indicated. (f, g) Combination of oxythiamine and imatinib suppresses BCR-ABL-expressing tumor growth in vivo. (f) Established tumors derived from imatinib-resistant cells (BR) were treated with phosphate-buffered saline (PBS) (n ¼ 5), oxythiamine (80 mg/kg per day, once daily) (n ¼ 6), imatinib (200 mg/kg per day, twice daily) (n ¼ 9) or oxythiamine plus imatinib (OT þ Im) (n ¼ 6) beginning 9 days after tumor initiation with 3 Â 10 6 cells, with the average tumor size around 100 mm 3
. Treatment was performed for 17 days by intraperitoneal injection. Shown is the relative increase in tumor mass ± s.e.m. Symbol ** indicates Po0.01 on day 20 and symbol * indicates Po0.05 on days 18, 23 and 25 between the combination treatment group and any other treatment group, as determined by unpaired Student's t-test. The effect of combining oxythiamine and imatinib through oral administration on tumor growth was also evaluated and a similar result was obtained (data not shown). (g) Established tumors derived from imatinib-sensitive cells (BS) were treated with PBS (n ¼ 4), oxythiamine (80 mg/kg per day) (n ¼ 6), imatinib (100 mg/kg per day) (n ¼ 6) or oxythiamine plus imatinib (OT þ Im) (n ¼ 5) beginning 13 days after tumor initiation with 1.5 Â 10 6 cells, with the average tumor size around 250 mm 3 . Treatment was performed once daily for 9 days through oral administration. Shown is the relative increase in tumor mass±s.e.m. Symbol ** indicates Po0.01 on day 22 between the combination treatment group and any other treatment group, as determined by unpaired Student's t-test.
HIF-1a control of nonoxidative PPP F Zhao et al HIF-1a was induced in response to high levels of BCR-ABL expression and was required to maintain the viability of such cells. The observed BCR-ABL induction of HIF-1a seems to lead to a relatively sustained conversion to aerobic glycolysis, just as hypoxic induction of HIF-1a leads to sustained anaerobic glycolysis.
Cells with high levels of BCR-ABL expression are at a growth disadvantage in comparison with cells with low levels of BCR-ABL, when BCR-ABL-induced glucose metabolism exceeds the capacity of a cell to assimilate or store glucose-derived carbon. BCR-ABL induces an increased expression of HIF-1a and glucose uptake. In part, BCR-ABL has been reported to increase HIF-1a through phosphatidylinositol-3-kinase activation (Mayerhofer et al., 2002) . The BCR-ABL induction of HIF-1a redirects glucose metabolism away from mitochondria (Gottschalk et al., 2004) . Although the induction of HIF-1a in response to excess glucose catabolism (Zhang et al., 2008) or hypoxia (Giuntoli et al., 2006) is cytoprotective, activation of HIF-1a reduces the synthetic capacity of the mitochondria and diverts glucose metabolism away from the oxidative arm of the PPP . The resulting decrease in the production of fatty acids, TCA-cycle-derived nonessential amino acids and ribose correlated with a reduced ability to proliferate. Thus, even in transformed cells, there seems to be a level of glucose metabolism that can paradoxically suppress in cis the proliferation of a cell.
Most cancer cells depend on de novo nucleotide biosynthesis for growth and survival (Zaharevitz et al., 1992) . This has been exploited in cancer therapy through the use of inhibitors of dihydrofolate reductase, thymidylate synthase, glutamine phosphoribosylpyrophosphate amidotransferase and adenosine deaminase. Ribose can be produced both in the oxidative and nonoxidative arms of the PPP. This has been interpreted to mean that an effective inhibitor of ribose synthesis would have to block both arms. Such drugs might thus have heightened toxicities for normal cells. Our data suggest that in cells depending on HIF-1a for continuous survival, effective ribose synthesis can only be maintained from the nonoxidative arm of the PPP. This suggests that inhibitors of nonoxidative PPP may have selective effects in tumors exhibiting constitutive HIF-1a activation. Such a targeted therapeutic use may limit the toxicity for nontransformed cells that retain an intact oxidative arm of the PPP. Consistent with this, oxythiamine, an inhibitor of thiamine-dependent enzymes, was found to synergize with imatinib in suppressing the growth and proliferation of BCR-ABL-transformed cells in vitro (Supplemental Figure 11) . The determination of how long such an effect can be sustained in chronically treated cells will require additional study.
In conclusion, our study provides insight into relative imatinib resistance associated with the increased BCR-ABL expression observed in leukemic cells of patients with accelerated CML. Collectively, the above observations support the hypothesis that the induction of HIF1a may contribute to the imatinib resistance exhibited by such cells. The ongoing development of HIF-1a inhibitors may soon allow this hypothesis to be tested. The potential ability of HIF-1a induction to reduce the oncogene addiction of BCR-ABL-transformed cells may be relevant to other oncogenes that activate the glucose metabolism of transformed cells, and this will need to be explored in future studies.
Materials and methods

Generation of imatinib-resistant cells, cell lines and reagents
All chemicals were from Sigma-Aldrich (St. Louis, MO, USA) and all cell culture reagents were from Invitrogen (Carlsbad, CA, USA) unless indicated otherwise.
The BCR-ABL-transformed murine hematopoietic BaF3 cell line (BaF3/p210) was established previously (Carroll et al., Oxythiamine enhances the efficacy of imatinib in primary chronic myeloid leukemia (CML) cells isolated from patients in the accelerated/blastic phase of the disease. Mononuclear cells (MNCs) from two patients at the accelerated phase of the disease were harvested and plated for colony formation, as described in the Materials and methods section, with indicated treatments. After 2 weeks, colonies were counted. The experiment was performed in triplicate and shown is the averaged number of colonies from each plate±s.e.m. Symbol ** indicates Po0.01, *** indicates Po0.001 and **** indicates Po0.0001, as determined by unpaired Student's t-test. Oxythiamine (OT), imatinib (Im) and thiamine (T) were added as indicated.
HIF-1a control of nonoxidative PPP F Zhao et al 1997). To generate imatinib-resistant cells, we incubated BaF3/ p210 cells in the presence of imatinib (0.5 or 1 mM), and the imatinib-supplemented culture medium was refreshed every 3 days until the outgrowth of a resistant population, after roughly 3 weeks. Isogenic sensitive cells (BS) were maintained at the same passage. The human imatinib-resistant LAMA-84-R cell line (LR) was generated and maintained as described previously (Mahon et al., 2000) . Imatinib-resistant cells were maintained with additional supplementation of either 0.5 mM (BR cells) or 1 mM (LR) imatinib, which was transiently withdrawn from the medium for the course of the experiments described in this study. For in vitro treatments with oxythiamine, we cultured BR and LR cells in F-12 Kaighn's nutrient mixture and McCoy's 5A medium with supplements, respectively. Human embryonic kidney 293T cell lines transfected with either vector or a nondegradable HIF-1a construct in an inducible system (HIF1A-DPA), CHO cells with or without G6PD deficiency and IL-3-dependent bax À/À bak À/À cells with or without knockdown of HIF-1a were described previously (Tuttle et al., 1992; Hu et al., 2003; Lum et al., 2007) .
Glucose uptake, quantitative PCR, constructs, cell transfection and antibodies Glucose concentration in the medium was determined as previously described . Total RNA was isolated using TRIzol Reagent (Invitrogen) and cDNA was prepared using SuperScript II Reverse Transcriptase (Invitrogen). All samples were normalized to b-actin transcript levels. A construct containing human Tktl1 cDNA was purchased from Invitrogen and cloned into a mammalian expression vector pEF6/MHC (Invitrogen). A construct containing a control short hairpin or an shRNA targeting mouse Tkt was purchased from Open Biosystems (Huntsville, AL, USA). Transfection was performed by nucleofector transfection (Lonza Walkersville Inc., Walkersville, MD, USA) using program X01 with 3 mg of DNA per 0.3 Â 10 6 cells. The following antibodies were used: c-Abl (Santa Cruz Biotechnology, Santa Cruz, CA, USA), phospho-694-STA-T5A/B (Upstate, Temecula, CA, USA), human HIF-1a (BD Biosciences, San Jose, CA, USA), mouse HIF-1a (a gift from Dr MC Simon) and b-actin (Sigma-Aldrich).
Transketolase activity In vitro Tkt activity was measured as previously described (Chamberlain et al., 1996) . Briefly, 3 Â 10 6 cells were washed with PBS before being lysed in M-PER cytosolic lysis buffer (Pierce Biotechnology, Rockford, IL, USA), supplemented with protease inhibitor (EDTA free) (Roche, Indianapolis, IN, USA) and phosphatase inhibitor cocktail (Sigma-Aldrich). Lysate (10 ml) was used in a 200 ml reaction mixture, containing 100 mM Tris chloride (pH 8.0), 15 mM ribose 5-phosphate, 250 mM NADH, 200 mU/ml glycerol-3-phosphate dehydrogenase and 2.5 U/ml triosephosphate isomerase. The absorbance at 340 nm (OD 340 ) was recorded every 10 min on a plate reader (Beckman, Brea, CA, USA). The OD difference between the 10 min point and each time point was normalized by protein amount.
